The Copenhagen-based team is building an AI platform to target underexplored GPCRs to treat diseases once deemed undruggable.

Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons, has filed for an IPO.

Researchers suggest targeting mTOR activity in aggressive cancers by blocking cholesterol sensing may represent a promising ...

By developing their own functional nerves, these organoids demonstrate how engineering principles can drive biological ...